Study of OL-101 for people with relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has returned or not responded to at least three prior treatments, including a specific type (PI), an immune drug (IMiD), and a targeted therapy (anti-CD38).
- Your disease got worse within 12 months of your last treatment, or it did not respond to your most recent therapy.
- You have measurable signs of the disease in your blood or urine, such as M-protein or free light chains.
- Your myeloma cells have a certain protein (BCMA or GPRC5D) on their surface; if you had BCMA therapy before, you must have GPRC5D on your cells.
- You are well enough to be up and about (ECOG score 0 or 1), and your organs like bone marrow, liver, kidneys, heart, and lungs are working adequately.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
This trial studies a new treatment called BR101 for people with multiple myeloma that has returned or not responded to previous treatments. The goal is to see if BR101 can help slow down or stop the cancer.
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.